You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Naqash AR, Cortellini A, Mi E, et al
32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0032